Clinical Trials Logo

Psychomotor Agitation clinical trials

View clinical trials related to Psychomotor Agitation.

Filter by:

NCT ID: NCT05261035 Completed - Muscle Disorder Clinical Trials

Stretching Exercises Versus Thermotherapy on Restless Legs Syndrome Symptoms

Exersize
Start date: June 5, 2021
Phase: N/A
Study type: Interventional

To compare the effects of stretching exercises versus thermotherapy on RLS symptoms and sleep quality among pregnant women. Research hypotheses: - Pregnant women who perform leg stretching exercises exhibit lower RLS symptoms severity and pain level than those who applied thermotherapy. - Pregnant women who perform leg stretching exercises exhibit higher sleep quality than those who applied thermotherapy.

NCT ID: NCT05249907 Completed - RLS Clinical Trials

Hemodialysis Patients With Restless Legs Syndrome Used Vibration

Start date: February 7, 2023
Phase: N/A
Study type: Interventional

Restless Legs Syndrome (RLS) is a chronic disorder characterized by abnormal sensations, usually accompanied by pain and restlessness in the legs and/or any part of the body. Sleep quality disorders (10-20%) and limb movements during sleep are quite common in patients with RLS . These disorders in sleep quality are also common among patients receiving hemodialysis due to end-stage renal disease. Pharmacological and non-pharmacological methods are used in the treatment of RLS. Due to the varying success and side effects of pharmacological treatments, non-pharmacological methods have come to the fore for these patients. One of the methods that can be applied as a non-pharmacological method is vibration. The therapeutic effect of instrument-assisted soft tissue manipulation (EYYDM) is not clear, it is stated that it activates the muscles, fascia and tendon and improves pain clinically in studies. The aim of the study is to determine the most effective treatment method on pain and sleep quality by comparing the effects of vibration and EYYDM methods in dialysis patients with restless legs syndrome

NCT ID: NCT05245721 Not yet recruiting - Post Operative Pain Clinical Trials

Effect of Caudal Nalbuphine on Postoperative Emergence Agitation in Pediatrics Undergoing Infra-umbilical Surgeries

Start date: March 2022
Phase: Phase 1
Study type: Interventional

Effect of caudal nalbuphine on postoperative emergence agitation in pediatrics undergoing infra-umbilical surgeries and pain assessment

NCT ID: NCT05223010 Completed - Emergence Agitation Clinical Trials

Melatonin for Pediatric Emergence Agitation

Start date: January 30, 2022
Phase: Phase 4
Study type: Interventional

efficacy of melatonin premedication on emergence agitation in children undergoing herniorrhaphy surgeries

NCT ID: NCT05214963 Completed - Clinical trials for Restless Legs Syndrome

Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS

Start date: March 8, 2022
Phase: N/A
Study type: Interventional

Prospective multi-site randomized sham-controlled study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS) who are either medication-naive or medication-refractory.

NCT ID: NCT05196828 Completed - Clinical trials for Restless Legs Syndrome

Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS

Start date: December 20, 2021
Phase: N/A
Study type: Interventional

Multi-center, prospective open-label extension study of noninvasive peripheral nerve stimulation (NPNS) with the NTX100 Neuromodulation System for patients with medication-refractory moderate- severe primary RLS

NCT ID: NCT05176119 Completed - Pediatric ALL Clinical Trials

Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy

Start date: March 25, 2021
Phase: Phase 4
Study type: Interventional

The effect of low dose nalbuphine or ketamine in the prevention of emergence agitation after sevoflurane anesthesia in children undergoing tonsillectomy with or without adenoidectomy. This randomized double-blind study was carried out at, Ain shams University Hospitals, from March 2021 to June 2021 on 90 patients after approval of the ethical committee.

NCT ID: NCT05165914 Completed - Agitation Clinical Trials

Midazolam Effect on Agitation Postnasal Surgery

Start date: May 27, 2021
Phase: N/A
Study type: Interventional

Postoperative agitation is a common complication, it's incidence post head and neck surgery is around 11-26%. Avoiding such complication is mandatory to facilitate patient's recovery and reduce risk of postoperative agitation related complications. Our study aims to detect the incidence of agitation following nasal surgery, and to determine the midazolam effect on agitation, when administered just before emergence from anesthesia.

NCT ID: NCT05164627 Active, not recruiting - Clinical trials for Postoperative Agitations in Pediatric Patients

Dexmedetomidine Versus Magnesium Infusion in Reducing Agitations in Pediatric Patients Undergoing Adenotonsillectomy

Start date: January 8, 2021
Phase: N/A
Study type: Interventional

The aim of this study is evaluating the efficacy and safety of dexmedetomidine versus Magnesium for reducing emergence agitation after adenotonsillectomy in children. Secondary outcome is to reduce child needs for analgesics and to reduce their dose.

NCT ID: NCT05163717 Terminated - Clinical trials for Agitation in Adolescents and Young Adults With ASD

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

CALM 201
Start date: June 23, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, proof-of concept, 2-way, 2-period crossover, double-blind study to evaluate the safety and efficacy of INP105 as an acute treatment versus placebo in adolescents and young adults with autism spectrum disorder (ASD) experiencing agitation. Approximately 32 ASD patients who are currently being treated for agitation/aggression at several inpatient units specializing in behavioral treatment will be enrolled. INP105 is a novel combination product that sprays a powder formulation of olanzapine to the upper nasal space. An earlier formulation showed a similar extent, but faster rate of absorption compared to the approved intramuscular product. In this study, 5 mg of olanzapine or placebo will be delivered nasally by this combination product to moderately or severely agitated participants. Participants will undergo several screening assessments, including observation session(s) of episode(s) of agitation resulting from a frustration task (eg, a non-preferred activity). At least one observation session must result in a documented moderate to severe agitation episode prior to the participant being eligible to enroll in the study and be randomized to treatment. The study will be conducted in 2 phases. A pilot phase will initially enroll at least 6 participants, who will receive both 5 mg INP105 (5 mg olanzapine) and placebo in random order, in the same crossover design as later participants. Participants will be dosed during a documented moderate to severe episode of agitation. Once 6 participants have completed both dosing periods and have at least 48 hours of post-dose safety data collected, a safety and preliminary efficacy analysis will be performed by an independent unblinded statistical group, and a summary report forwarded to a sponsor-led Data and Safety Review Committee (DSRC), who will remain blinded. Enrollment will be paused during the DSRC pilot phase safety and preliminary efficacy results review. Absent any concerning safety signals, the second phase will enroll all remaining participants. The DSRC may suggest revisions to the protocol, and the protocol amended and approved as necessary, prior to further participants being enrolled.